Stock Scorer

Tenon Medical, Inc. (TNON)

Tenon Medical, Inc. reported revenue of 1.3M USD for the quarter ending 30 June 2026, up 126.8% from 564K a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 1.3M +126.8%
Gross Profit Q2 '26 · ending 30 June 2026 814K +232.2%
Operating Income Q2 '26 · ending 30 June 2026 -3.4M —
Net Income Q2 '26 · ending 30 June 2026 -4M —
Cost of Revenue Q2 '26 · ending 30 June 2026 465K +45.8%
Operating Cash Flow Q2 '26 · ending 30 June 2026 -2.8M —
Free Cash Flow Q2 '26 · ending 30 June 2026 -2.9M —
Shares Outstanding Q2 '26 · ending 30 June 2026 328 -90.9%
EPS 2025 · ending 31 December 2025 -1.70 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 3.9M-12.8M-12.6M-11M
20242024-12-31 3.3M-13.8M-13.7M-10.1M
20232023-12-31 2.9M-15.7M-15.6M-12.5M
20222022-12-31 691K-18.7M-18.9M-12.9M
20212021-12-31 160K-6.5M-7M-4.4M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-301.3M
Q1 '262026-03-311.4M
Q4 '252025-12-311.5M
Q3 '252025-09-301.2M
Q2 '252025-06-30564K
Q1 '252025-03-31726K
Q4 '242024-12-31770K
Q3 '242024-09-30887K
Q2 '242024-06-30901K
Q1 '242024-03-31719K
Q4 '232023-12-31808K
Q3 '232023-09-30944K
Q2 '232023-06-30743K
Q1 '232023-03-31433K
Q4 '222022-12-31277K
Q3 '222022-09-30208K
Q2 '222022-06-30135K
Q1 '222022-03-3171K
Q4 '212021-12-3153K
Q3 '212021-09-3070K

Gross Profit Quarterly

PeriodEndingGross Profit
Q2 '262026-06-30814K
Q1 '262026-03-31945K
Q4 '252025-12-311M
Q3 '252025-09-30773K
Q2 '252025-06-30245K
Q1 '252025-03-31323K
Q4 '242024-12-31353K
Q3 '242024-09-30418K
Q2 '242024-06-30470K
Q1 '242024-03-31470K
Q4 '232023-12-31559K
Q3 '232023-09-30535K
Q2 '232023-06-30194K
Q1 '232023-03-31-47K
Q4 '222022-12-31-207K
Q3 '222022-09-30-94K
Q2 '222022-06-30-136K
Q1 '222022-03-31-204K
Q4 '212021-12-3136K
Q3 '212021-09-3052K

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-3.4M
Q1 '262026-03-31-3.3M
Q4 '252025-12-31-2.9M
Q3 '252025-09-30-3.4M
Q2 '252025-06-30-2.9M
Q1 '252025-03-31-3.7M
Q4 '242024-12-31-3.2M
Q3 '242024-09-30-3.2M
Q2 '242024-06-30-3.9M
Q1 '242024-03-31-3.5M
Q4 '232023-12-31-3.1M
Q3 '232023-09-30-3.4M
Q2 '232023-06-30-4.3M
Q1 '232023-03-31-4.9M
Q4 '222022-12-31-7.9M
Q3 '222022-09-30-3.3M
Q2 '222022-06-30-5.5M
Q1 '222022-03-31-2.1M
Q4 '212021-12-31-2.6M
Q3 '212021-09-30-2.1M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-4M
Q1 '262026-03-31-3.5M
Q4 '252025-12-31-2.8M
Q3 '252025-09-30-3.3M
Q2 '252025-06-30-2.8M
Q1 '252025-03-31-3.6M
Q4 '242024-12-31-3.1M
Q3 '242024-09-30-3.2M
Q2 '242024-06-30-3.8M
Q1 '242024-03-31-3.6M
Q4 '232023-12-31-3.1M
Q3 '232023-09-30-3.3M
Q2 '232023-06-30-4.3M
Q1 '232023-03-31-4.8M
Q4 '222022-12-31-7.9M
Q3 '222022-09-30-3.2M
Q2 '222022-06-30-5.5M
Q1 '222022-03-31-2.4M
Q4 '212021-12-31-2.8M
Q3 '212021-09-30-2.3M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q2 '262026-06-30465K
Q1 '262026-03-31434K
Q4 '252025-12-31464K
Q3 '252025-09-30400K
Q2 '252025-06-30319K
Q1 '252025-03-31403K
Q4 '242024-12-31417K
Q3 '242024-09-30469K
Q2 '242024-06-30431K
Q1 '242024-03-31249K
Q4 '232023-12-31249K
Q3 '232023-09-30409K
Q2 '232023-06-30549K
Q1 '232023-03-31480K
Q4 '222022-12-31484K
Q3 '222022-09-30302K
Q2 '222022-06-30271K
Q1 '222022-03-31275K
Q4 '212021-12-3117K
Q3 '212021-09-3018K

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-2.8M
Q1 '262026-03-31-3M
Q4 '252025-12-31-2.2M
Q3 '252025-09-30-3.8M
Q2 '252025-06-30-2.2M
Q1 '252025-03-31-2.5M
Q4 '242024-12-31-2.8M
Q3 '242024-09-30-2.3M
Q2 '242024-06-30-2.4M
Q1 '242024-03-31-2.3M
Q4 '232023-12-31-2.3M
Q3 '232023-09-30-3.2M
Q2 '232023-06-30-3.2M
Q1 '232023-03-31-3.6M
Q4 '222022-12-31-3.4M
Q3 '222022-09-30-3.4M
Q2 '222022-06-30-2.8M
Q1 '222022-03-31-2.5M
Q4 '212021-12-31-1.7M
Q3 '212021-09-30-1.4M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30-2.9M
Q1 '262026-03-31-3M
Q4 '252025-12-31-2.4M
Q3 '252025-09-30-3.9M
Q4 '242024-12-31-2.8M
Q3 '242024-09-30-2.4M
Q2 '242024-06-30-2.4M
Q1 '242024-03-31-2.5M
Q4 '232023-12-31-2.4M
Q3 '232023-09-30-3.2M
Q2 '232023-06-30-3.3M
Q1 '232023-03-31-3.7M
Q4 '222022-12-31-4M
Q3 '222022-09-30-3.5M
Q2 '222022-06-30-2.8M
Q1 '222022-03-31-2.6M
Q4 '212021-12-31-1.8M
Q3 '212021-09-30-1.4M
Q2 '212021-06-30-1M
Q1 '212021-03-31-162K

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-30328
Q1 '262026-03-3111.3K
Q3 '252025-09-308.2K
Q2 '252025-06-30217
Q1 '252025-03-313.6K
Q3 '242024-09-30877
Q2 '242024-06-30469
Q1 '242024-03-31357
Q3 '232023-09-30285
Q2 '232023-06-301.3K
Q1 '232023-03-311.1K
Q3 '222022-09-301.1K
Q2 '222022-06-308.4K
Q1 '222022-03-31990
Q3 '212021-09-30919
Q2 '212021-06-30830

EPS Annual

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
FY252025-12-31-1.70
FY242024-12-31-11.26
FY232023-12-31-68.64
FY222022-12-31-23.62
FY212021-12-31-7.81